Zejula

Zejula (niraparib tosylate monohydrate) is an oral prescription medication used in cancer care. It belongs to a class of drugs known as PARP inhibitors. This product is manufactured in the EU and intended for oral administration.

Zejula is used in the maintenance treatment of certain types of ovarian, fallopian tube, or primary peritoneal cancer. It may be prescribed after a patient has responded to platinum-based chemotherapy. The medication works by helping to prevent cancer cells from repairing their DNA, which can slow the growth of tumors. Patients often ask, 'what is niraparib used for' or 'niraparib tosylate monohydrate uses' when considering treatment options.

As a PARP inhibitor, niraparib tosylate monohydrate may help stabilize disease or slow progression in eligible patients. Common effects include gastrointestinal changes such as nausea or digestive discomfort. Some individuals may experience fatigue or changes in blood cell counts, which are monitored during treatment.

Zejula should be taken exactly as prescribed by a healthcare provider. It is important to attend all scheduled blood tests and follow-up appointments to monitor for potential side effects. Patients should inform their doctor about any other medications or supplements they are taking before starting this treatment.

Niraparib tosylate monohydrate may interact with other drugs, including certain antidepressants, antifungals, and blood thinners. Combining it with strong CYP3A inhibitors or inducers can affect how the medication works. Alcohol use should be discussed with a healthcare provider, as it may influence treatment tolerance.